Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US.

Future oncology (London, England) - 1 Dec 2025

Schoenfeld Adam J, Hu Chen, Rajaram Ravi, Feliciano Josephine, Chandran Urmila, Wong Charlene, Kalsekar Iftekhar, Wang Tianyi, Huang Qing, Hasan Aisha

Abstract excerpt

AIMS: Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) inhibitors (PD-[L]1) are standard of care for patients with metastatic non-small cell lung cancer (mNSCLC). This study examined real-world treatment patterns and attrition by lines of therapy (LOTs) among patients with non-driver mutation mNSCLC. PATIENTS & METHODS: A retrospective study of adult patients with mNSCLC (2015‒2022) who received ≥1 systemic...

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung
Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Practice Patterns, Physicians'

Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41346283
DOI: 10.1080/14796694.2025.2592721
PMCID: PMC12758327

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US.PMID 41346283Read ↗

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.Semantic proximity Read ↗

Treatment Patterns Across Lines of Therapy for Advanced Non-Small Cell Lung Cancer in the United States.Semantic proximity Read ↗

Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021-2026.Semantic proximity Read ↗

Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.Semantic proximity Read ↗

Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United KingdomSemantic proximity Read ↗

Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact® survey 2021.Semantic proximity Read ↗

Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival OutcomesSemantic proximity Read ↗

Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.Semantic proximity Read ↗

Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study.Semantic proximity Read ↗

Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England.Semantic proximity Read ↗

Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.